Clinical Trial Detail

NCT ID NCT02184195
Title Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

pancreatic adenocarcinoma

Therapies

Olaparib

Age Groups: senior adult

No variant requirements are available.